(Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effective. The encouraging data allows the companies to begin final-stage Phase III asthma trials on the medicine, which is also being developed for atopic dermatitis and chronic sinusitis with nasal polyps. Dupilumab is one of the new medicines Sanofi is expected discuss at an investor day on Nov. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment